Experimental Studies Indicate That ST-2223, the Antagonist of Histamine H3 and Dopamine D2/D3 Receptors, Restores Social Deficits and Neurotransmission Dysregulation in Mouse Model of Autism

dc.contributor.authorEissa, Nermin
dc.contributor.authorVenkatachalam, Karthikkumar
dc.contributor.authorJayaprakash, Petrilla
dc.contributor.authorYuvaraju, Priya
dc.contributor.authorFalkenstein, Markus
dc.contributor.authorStark, Holger
dc.contributor.authorSadek, Bassem
dc.date.accessioned2023-05-01T05:37:13Z
dc.date.accessioned2023-08-19T08:56:31Z
dc.date.available2023-05-01T05:37:13Z
dc.date.available2023-08-19T08:56:31Z
dc.date.issued2022-07
dc.description.abstractAltered regulation of neurotransmitters may lead to many pathophysiological changes in brain disorders including autism spectrum disorder (ASD). Given the fact that there are no FDAapproved effective treatments for the social deficits in ASD, the present study determined the effects of chronic systemic treatment of the novel multiple-active H3R/D2R/D3R receptor antagonist ST-2223 on ASD-related social deficits in a male Black and Tan Brachyury (BTBR) mice. ST-2223 (2.5, 5, and 10 mg/kg, i.p.) significantly and dose-dependently mitigated social deficits and disturbed anxiety levels of BTBR mice (p < 0.05) in comparison to the effects of aripiprazole (1 mg/kg, i.p.). Moreover, levels of monoaminergic neurotransmitters quantified by LC-MS/MS in four brain regions including the prefrontal cortex, cerebellum, striatum, and hippocampus unveiled significant elevation of histamine (HA) in the cerebellum and striatum; dopamine (DA) in the prefrontal cortex and striatum; as well as acetylcholine (ACh) in the prefrontal cortex, striatum, and hippocampus following ST-2223 (5 mg/kg) administration (all p < 0.05). These in vivo findings demonstrate the mitigating effects of a multiple-active H3R/D2R/D3R antagonist on social deficits of assessed BTBR mice, signifying its pharmacological potential to rescue core ASD-related behaviors and altered monoaminergic neurotransmitters. Further studies on neurochemical alterations in ASD are crucial to elucidate the early neurodevelopmental variations behind the core symptoms and heterogeneity of ASD, leading to new approaches for the future therapeutic management of ASD.
dc.description.abstractEissa, N., Venkatachalam, K., Jayaprakash, P., Yuvaraju, P., Falkenstein, M., Stark, H., & Sadek, B. (2022). Experimental Studies Indicate That ST-2223, the Antagonist of Histamine H3 and Dopamine D2/D3 Receptors, Restores Social Deficits and Neurotransmission Dysregulation in Mouse Model of Autism. Pharmaceuticals, 15(8), 929.
dc.identifier.citationEissa, N., Venkatachalam, K., Jayaprakash, P., Yuvaraju, P., Falkenstein, M., Stark, H., & Sadek, B. (2022). Experimental Studies Indicate That ST-2223, the Antagonist of Histamine H3 and Dopamine D2/D3 Receptors, Restores Social Deficits and Neurotransmission Dysregulation in Mouse Model of Autism. Pharmaceuticals, 15(8), 929.
dc.identifier.urihttps://edms.wexl.in/handle/1/4700
dc.subjectSocial Deficits
dc.subjectNeurotransmitters
dc.subjectHistamine H3R Antagonist
dc.subjectDopamine D2R/D3R Antagonist
dc.titleExperimental Studies Indicate That ST-2223, the Antagonist of Histamine H3 and Dopamine D2/D3 Receptors, Restores Social Deficits and Neurotransmission Dysregulation in Mouse Model of Autismen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
pharmaceuticals-15-00929.pdf
Size:
1.98 MB
Format:
Adobe Portable Document Format
Description:
Experimental Studies Indicate That ST-2223, the Antagonist of Histamine H3 and Dopamine D2/D3 Receptors, Restores Social Deficits and Neurotransmission Dysregulation in Mouse Model of Autism

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:

Collections